Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 CMX-020 study in active knee osteoarthritis
ACTRN12616001435471Phase 2Terminated
- Sponsor
- Cytometix
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of CMX-020 in osteoarthritis (OA) and knee osteoarthritis (OA) (4 arms), sponsored by Cytometix. Primary endpoint: Change in pain visual analogue scale score. Started Dec 2016; status: terminated.
02
Drugs
CMX-020
03
Conditions
osteoarthritis (OA)knee osteoarthritis (OA)
Beyond the preview
Go deeper on ACTRN12616001435471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001435471.